L'intérêt à découvert pour TNF Pharmaceuticals donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de TNF Pharmaceuticals. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

TNF Pharmaceuticals (NASDAQ:TNFA) Stock, Rapport sur les intérêts à découvert

TNF Pharmaceuticals

MyMD Pharmaceuticals

TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine.

TNF Pharmaceuticals Inc

WIIM

SLDB

Solid Biosciences shares are trading higher after the company announced it received FDA Fast Track Designation status for SGT-501 gene therapy.

Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) and BNY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) have introduced a blockchain-powered system to issue digital tokens that mirror shares of money market funds, marking a significant step toward the <a href="https://www.benzinga.com/markets/25/07/46420155/the-tokenization-market-has-a-4-000x-growth-potential-according-bitwise-heres-the-cleanest-way-to-in">tokenization of traditional financial assets in the United States</a>.
As part of this <a href="https://www.bny.com/corporate/global/en/about-us/newsroom/company-news/bny-and-goldman-sachs-launch-tokenized-money-market-funds-solution.html">initiative</a>, institutional investors can now subscribe to select money market funds via BNY&#8217;s LiquidityDirect platform, with mirror tokens issued using Goldman Sachs&#8217; GS DAP&#xAE; blockchain infrastructure. 
These digital representations will reflect the corresponding value of investors&#8217; holdings and allow enhanced visibility, programmability, and potential future transferability of fund shares.
The launch includes participation from several prominent fund managers, such as BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>), Fidelity Investments, Goldman Sachs Asset Management, Federated Hermes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHI#NYSE">FHI</a>), and BNY Investments Dreyfus.
BNY will maintain the official records and settlements, while the tokens are created in parallel using GS DAP&#xAE;, a blockchain platform developed by Goldman Sachs Digital Assets.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46570852/coinbase-strategy-under-the-microscope-in-south-koreas-etf-market-should-you-be-concerned?utm_campaign=Watchlist&amp;utm_source=Benzinga&amp;utm_medium=Email">Coinbase, Strategy Under The Microscope In South Korea&#8217;s ETF Market—Should You Be Concerned?</a>
The goal is to improve fund utility in the long term by enabling the shares to potentially be used as collateral and transferred more seamlessly.
"As the financial system transitions toward a more digital, real-time architecture, BNY is committed to enabling scalable and secure solutions that shape the future of finance," said Laide Majiyagbe, Global Head of Liquidity, Financing and Collateral at BNY.
Mathew McDermott, Global Head of Digital Assets at Goldman Sachs, emphasized the broader implications: "Using tokens representing the value of shares of Money Market Funds on GS DAP&#xAE; would enable us to unlock their utility as a form of collateral."
This marks the first U.S. deployment of mirrored tokenization for MMFs, positioning both financial institutions at the forefront of integrating blockchain into mainstream fund operations.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46567973/ethereum-treasury-company-trend-will-accelerate-says-bitwises-matt-hougan-heres-what-it-means-for-eths-price">Ethereum Treasury Company Trend &#8216;Will Accelerate&#8217;, Says Bitwise&#8217;s Matt Hougan—Here&#8217;s What It Means For ETH&#8217;s Price</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

BNY Taps Goldman Tech To Tokenize Traditional Finance—BlackRock, Fidelity Join In

SCLX

Scilex Holding shares are trading higher after the company announced it entered into a $100 million common stock purchase agreement with Tumim Stone Capital.

HAFC

Hanmi Financial shares are trading lower after the company reported worse-than-expected Q2 financial results.

Scotiabank analyst Phil Hardie maintains TMX Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/X#TSX">X</a>) with a Sector Perform and raises the price target from C$57 to C$63.

Price Target

Analyst Ratings

TSX:X

Scotiabank Maintains Sector Perform on TMX Group, Raises Price Target to C$63

Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) has outperformed the market over the past 5 years by 4.8% on an annualized basis producing an average annual return of 19.25%. Currently, Netflix has a market capitalization of $500.60 billion. 
Buying $100 In NFLX: If an investor had bought $100 of NFLX stock 5 years ago, it would be worth $237.68 today based on a price of $1178.09 for NFLX at the time of writing.
<h3>Netflix's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753281916_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

NFLX

Here's How Much $100 Invested In Netflix 5 Years Ago Would Be Worth Today

HCSG

Healthcare Services Group shares are trading higher after the company reported Q2 financial results and beat its adjusted EPS and revenue estimates.

On July&nbsp;21, 2025, Simmons First National Corporation (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Stephens Inc., Keefe, Bruyette&nbsp;&amp; Woods, Inc. and Morgan Stanley&nbsp;&amp; Co. LLC as representatives of the several underwriters named in Schedule A thereto (the "Underwriters"), pursuant to which the Company agreed to issue and sell 18,653,000 shares of the Company's Class&nbsp;A common stock, par value $0.01 per share (the "Common Stock"), to the Underwriters (the "Offering") (including 2,433,000 shares pursuant to the Underwriters' option to purchase additional shares of Common Stock in the Offering (the "Option Shares")). The public offering price of shares of Common Stock sold in the Offering is $18.50 per share, and the Underwriters have agreed to purchase the shares from the Company pursuant to the Underwriting Agreement at a price of $17.575 per share. The Offering closed on July 23, 2025.
The net proceeds to the Company from the Offering, including the exercise by the Underwriter of its 30-day option to purchase any of the Option Shares, are expected to be approximately $326.9&nbsp;million after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the proceeds from the Offering for general corporate purposes, which may include investments in Simmons Bank to support a potential balance sheet repositioning and continued growth.
The Offering was made pursuant to the Company's Registration Statement on Form S-3ASR (File No.&nbsp;333-279502), which was previously filed with the Securities and Exchange Commission and automatically effective as of May&nbsp;17, 2024, as supplemented by a prospectus supplement, dated July&nbsp;21, 2025.

Offerings

SFNC

Simmons First National Raises $327M In Public Offering Of 18.7M Shares At $18.50 Each

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing &#8220;gray&#8221; market for purchasing active ingredients from China, <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/stung-by-high-prices-americans-make-their-own-weight-loss-drugs-2025-06-27/">Reuters reported</a> recently.
Reuters cited a 44% monthly increase in January in shipments of tirzepatide and semaglutide from Chinese suppliers not registered with the U.S. Food and Drug Administration, according to data from the Partnership for Safe Medicines. The gray market — named because the drugs are technically legal to buy for &#8220;research purposes&#8221; — provides users with GLP-1 compounds, including semaglutide, tirzepatide and even retatrutide, which is still in clinical trials, in powder form for as little as $50 a vial. Buyers then mix the powder with bacteriostatic water at home to create an injectable solution.
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – Many are rushing to grab <a href="https://www.benzinga.com/money/mode-mobile-2">4,000 of its pre-IPO shares for just $0.30/share</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
Without insurance, the monthly cost of these drugs starts at around $500 and <a href="https://www.kff.org/affordable-care-act/press-release/costly-glp-1-drugs-are-rarely-covered-for-weight-loss-by-marketplace-plans/#:~:text=Of%20the%20few%20Marketplace%20plans,employ%20similar%20utilization%20management%20strategies.">can exceed $1,000</a>. A survey by the International Foundation of Employee Benefit Plans <a href="https://www.ifebp.org/resources---news/survey-reports/glp-1-drugs-us--2025-pulse-survey">found</a> that 36% of employer health plans will cover GLP-1 drugs for obesity in 2025. In April, the Trump administration <a href="https://public-inspection.federalregister.gov/2025-06008.pdf">also announced</a> that Medicare and Medicaid would not cover anti-obesity medications, which includes the GLP-1 class.
<h2 class="wp-block-heading">Buyer Communities Try to Mitigrate Gray Market Risks</h2>
However, the DIY gray market carries significant risks. Some buyers attempt to reduce these risks by sending powders to labs for purity testing before use. Janoshik Analytical CEO Peter Magic told Reuters that the Czech Republic-based lab tested 3,050 samples of obesity drugs in 2024, up from just over 650 the previous year.
Yet the at-home mixing process still introduces human error. Amy Spencer, a Missouri woman interviewed by Reuters, said she reduced her monthly cost from more than $500 for brand-name GLP-1s to $50 on the gray market. But she accidentally overdosed after a reconstitution miscalculation, suffering severe flu-like symptoms for four days.
Trending: This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — <a href="https://www.benzinga.com/money/finally-a-fully-automated-trading-platform-for-individual-investors?">You Can Become an Investor for Just $500.25</a>
<h2 class="wp-block-heading">FDA Ruling a Driving Factor to Going Gray</h2>
If that level of risk sounds overwhelming to navigate, rest assured, passengers navigating the world of gray market peptides are hardly alone. Subreddits like "<a href="https://www.reddit.com/r/SemaglutideFreeSpeech/">SemaglutideFreeSpeech</a>" can provide some hand-holding, and also direct users to outside resources on more secretive channels, like Telegram. Many users on the subreddit are being directed to "go gray" after <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize">FDA rulings</a> essentially halted the ability of compounding pharmacies to sell cheaper versions of the medicines. The FDA had temporarily allowed compounding of the GLP-1 drugs semaglutide and tirzepatide during shortages because federal law permits copycat versions when FDA-approved drugs are listed as scarce. When the shortages were resolved, however, the exemption ended — as did a cheaper alternative to brand-name GLP-1 drugs. Some compounders are trying to continue business as usual with workarounds like <a href="https://www.goodrx.com/classes/glp-1-agonists/compounded-glp-1-going-away">adding vitamin b12</a>, to differentiate the medications from the FDA-approved versions.
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
<h2 class="wp-block-heading">Drug Companies, State Attorneys Respond</h2>
The gray market hasn't gone unnoticed by regulators and drug companies alike. <a href="https://www.benzinga.com/quote/LLY">Eli Lilly</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), maker of GLP-1s Monjouro and Zepbound, and <a href="https://www.benzinga.com/quote/NVO">Novo Nordisk</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) said they're combating unsafe products through lawsuits and consumer education, Reuters reports. Meanwhile on the customs front, the FDA does intercept some illegal imports, although personal-use buyers are rarely prosecuted.
Attorneys general from 38 U.S. states and territories also warned the FDA in February about illegally sold weight-loss drugs, including unregulated ingredients from China, Reuters reports. &#8220;It can be very dangerous. You&#8217;re playing the role of your own doctor, pharmacist, and FDA inspector,&#8221; Shabbir Safdar, executive director of the Partnership for Safe Medicines, said in a statement to Reuters.
Read Next: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
Image: Shutterstock

Personal Finance

Americans Are Turning To DIY Weight Loss Injections to Dodge $1,000+ Monthly Drug Costs

A common complaint in the American healthcare debate is that physicians <a href="https://www.benzinga.com/personal-finance/management/25/07/46359087/after-saving-1-3-million-at-35-this-doctor-wonders-if-its-finally-lamborghini-time">make too much money</a>, and that their pay is a major reason healthcare is so expensive. But a U.S. surgeon recently spent an administrative day crunching the numbers, and he argues the reality doesn't match the outrage.
&#8220;Physician salaries account for roughly 8.6% of total healthcare costs [in the U.S.],&#8221; the surgeon wrote in a Reddit <a href="https://www.reddit.com/r/Salary/comments/1m2cpj6/physicians_make_too_much_and_thats_why_healthcare/">post</a> on r/Salary. &#8220;It's around 10% in Canada, 15% in Germany, 11% in France, 11.6% in Australia, and 9.7% in the UK.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – Many are rushing to grab <a href="https://www.benzinga.com/money/mode-mobile-2">4,000 of its pre-IPO shares for just $0.30/share</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
<h2 class="wp-block-heading">A Closer Look At The Numbers</h2>
He also did his own calculations using Canadian healthcare spending figures. Canada spent $372 billion on healthcare last year. With an average physician salary of $384,000 and 97,384 physicians nationwide, the total salary cost works out to about $37.4 billion—roughly 10% of total healthcare spending.
That figure aligns closely with the U.S., suggesting that doctors' share of healthcare spending isn't uniquely bloated in America. &#8220;This just means that our healthcare system as a whole is riddled by parasites such as insurance companies and admin,&#8221; he added.
Critics often argue that U.S. physicians earn much more than their international peers. But when the Reddit poster compared salaries of engineers, teachers, lawyers and plumbers in the U.S., Canada, Germany, and France, he found similar ratios to physician salaries across all professions.
Trending: This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — <a href="https://www.benzinga.com/money/finally-a-fully-automated-trading-platform-for-individual-investors?">You Can Become an Investor for Just $500.25</a>
For example, the ratio of physician to engineer pay was 2.7 in the U.S., compared to 3.2 in Canada and 1.9 in Germany. When it came to teachers, the ratio was 4.1 in the U.S. and 4.7 in Canada. &#8220;It seems like Germany underpays teachers relative to physicians, but the USA is very close to France and Canada,&#8221; he noted.
<h2 class="wp-block-heading">So What's Actually Driving Costs?</h2>
Commenters overwhelmingly agreed that doctors aren't the problem. &#8220;Healthcare is now the largest employer in the country and it&#8217;s got very little to do with doctors, nurses and surgeons,&#8221; one person wrote. &#8220;It's admin. It's always been admin,&#8221; said another. &#8220;There are, what, a dozen administrators per doctor in the average hospital?&#8221;
Medical equipment sales, <a href="https://www.benzinga.com/news/25/05/45389750/trump-claims-drug-price-crackdown-could-slash-your-prescription-costs-by-59-but-will-big-pharma-fight-it-again">pharmaceutical pricing</a>, and insurance company practices were also frequently blamed. &#8220;Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) generated +$20 billion in 2024,&#8221; one commenter said. Another added, &#8220;We're paying double what we should for care, not 6% more.&#8221;
The thread also dug into why <a href="https://www.benzinga.com/news/topics/25/07/46251302/mark-cuban-says-med-school-should-be-free-for-10b-a-year-we-would-see-a-change-in-the-profession-career-paths-and-the-cost-of-care">training more doctors</a> isn't as simple as it sounds. Opening more residency spots requires adequate patient volume and teaching staff resources that aren&#8217;t easy to scale overnight. &#8220;You need to do X number of Y procedures to be competent,&#8221; the surgeon explained. &#8220;It&#8217;s not as easy as just &#8216;training more doctors&#8217;. There are many moving parts.&#8221;
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
Meanwhile, some emphasized the optics: the public sees doctors <a href="https://www.benzinga.com/personal-finance/25/04/45056965/dave-ramsey-says-doctors-and-lawyers-are-like-actors-notoriously-bad-with-money-just-because-you-make-a-lot-doesnt-mean-youre-winning">making six or seven figures</a> and assumes they are to blame, even though health insurance CEOs routinely earn $20 million or more. &#8220;Physicians are easy targets,&#8221; one longtime medical professional wrote. &#8220;We are much more poorly organized than big pharma or the hospital lobby.&#8221;
Others chimed in from outside medicine. &#8220;Make a button on an app more responsive and get $500K, no one cares. Save lives and make $300K, pitchforks,&#8221; one person joked. A dentist said their patients wrongly assume they keep the entire cost of a procedure. &#8220;For a cancer procedure that costs over $20,000 before insurance, I take home $1,600. But laypeople think I take home all $20,000.&#8221;
One user summed it up plainly: &#8220;Anyone who thinks physicians make too much money is an idiot. I&#8217;m not a physician, I work in tech. But I&#8217;d rather fire every insurance company admin and funnel that money back into pay for doctors, nurses and other people doing the actual useful jobs.&#8221;
Read Next: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Image: Shutterstock

Many Think Doctors Are Overpaid And That's Why Healthcare Is So Pricey, But One U.S. Surgeon Actually Ran The Numbers Against Global Peers

Truist Securities analyst Scot Ciccarelli maintains Genuine Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) with a Buy and raises the price target from $137 to $143.

Truist Securities Maintains Buy on Genuine Parts, Raises Price Target to $143

Scotiabank analyst Phil Hardie maintains Trisura Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TSU#TSX">TSU</a>) with a Sector Outperform and raises the price target from C$50 to C$51.

TSX:TSU

Scotiabank Maintains Sector Outperform on Trisura Group, Raises Price Target to C$51

HUMA

Humacyte shares are trading higher after the company announced the first Symvess sale to a U.S. military treatment facility.

Live On CNBC, KeyCorp CEO Christopher Gorman Says Does Not See Consumers Significantly Impacted By Tariffs

Truist Securities analyst Michael Roxland reiterates Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) with a Hold and raises the price target from $117 to $118.

Reiteration

Truist Securities Reiterates Hold on Crown Holdings, Raises Price Target to $118

Scotiabank analyst Phil Hardie maintains Propel Holdings (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PRL#TSX">PRL</a>) with a Sector Outperform and raises the price target from C$38 to C$43.

TSX:PRL

Scotiabank Maintains Sector Outperform on Propel Holdings, Raises Price Target to C$43

Wayfair shares are trading higher after Wells Fargo raised its price target on the stock from $50 to $65.

Truist Securities analyst Michael Ciarmoli downgrades Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) from Buy to Hold and lowers the price target from $554 to $440.

Downgrades

Truist Securities Downgrades Lockheed Martin to Hold, Lowers Price Target to $440

Grupo Televisa shares are trading higher after Benchmark raised its price target on the stock from $7 to $9.

Travel Leisure shares are trading higher after the company reported a Q2 sales beat.

Press Releases

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025

TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists

Comments

TNF Pharmaceuticals

Intérêt court

TNF Pharmaceuticals (NASDAQ:TNFA) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL